A trial with 18 rectal cancer patients produced a remarkable breakthrough in cancer research as all patients were cured and did not need to pursue additional cancer treatments.
The "unprecedented" and "remarkable" results of a small cancer trial that left every patient in remission are being praised.
A study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and were cancer-free, including the first patient who is now two years out of the trial, w...
